NDC: Niche pharmaceutical franchise with mid-single-digit growth and limited upside at current price
Intrinsic value VND 175,620 vs market price VND 157,000 — implied upside 11.9% (model confidence: low).
Tổng quan doanh nghiệp
Công ty Cổ phần Nam Dược (NDC) is a UPCoM-listed pharmaceutical company operating in the Vietnamese domestic consumer healthcare and pharmaceutical segment (ICB: Dược phẩm). The company generated revenue of VND 928.0 bn in 2025 after peaking at VND 949.7 bn in 2024, with gross margin at 51.8% and an EBIT margin of 11.2% in the latest period. NDC appears to run a capital-light model with net cash on the balance sheet (net_debt reported as negative in the valuation inputs). Key shareholders include two institutional holders (Promind 21.6%, Dược Phẩm Ích Nhân 19.6%) and a controlling individual (Dương Thị Sáu 23.8%), indicating concentrated ownership.
Luận điểm đầu tư
NDC combines a defensible domestic brand with attractive unit economics: ROE of 14.6% and ROA of 11.5% alongside a high gross margin of 51.8%, which supports steady cash generation (base FCF input VND 77.5 bn). The company’s P/E of 12.8 and P/B of 1.8 are moderate versus peers, and net cash (model net_debt equivalent to roughly VND 66.0 bn) provides balance-sheet optionality for buybacks or dividend distribution.
However, growth has softened: revenue fell to VND 928.0 bn in 2025 from VND 949.7 bn in 2024, and net profit declined to VND 90.1 bn (2025). The valuation implies only an 11.9% upside to intrinsic value VND 175,620, and the model flags low confidence driven by illiquidity and calibration (confidence: low; sanity flag: "illiquid"). Execution risk around restoring top-line growth and converting margins into sustained free cash flow is the main operational concern. Concentrated ownership (largest holder 23.8%) also raises governance considerations for minority investors.
Given the limited implied upside (11.9%) and low model confidence, the expected return does not clearly compensate for execution and liquidity risk. The stock retains defensive qualities (high gross margin, net cash, ROE ~14.6%) but lacks a clear catalyst that would justify a high-conviction re-rating at current levels.
Diễn giải định giá
Blended valuation using a 70/30 mix of a DCF and relative PE-derived intrinsic values to produce a blended intrinsic value per share.
- DCF inputs: base FCF VND 77.5 bn, WACC 10.0%, terminal growth 4.0%, projection period 10 years; terminal value accounts for ~57.1% of DCF value.
- PE inputs: fair PE used in the PE leg is 7.92 with a PE cap of 25, producing a PE-based intrinsic of VND 119,640 per share.
- Balance-sheet: reported net cash (net_debt negative ≈ VND 66.0 bn) contributes positively to enterprise value.
- Model calibration: raw intrinsic value before isotonic calibration was VND 201,231; final blended intrinsic is VND 175,620 after recalibration (confidence: low).
The blended intrinsic value VND 175,620 implies 11.9% upside to the market price of VND 157,000. Confidence is low due to illiquidity and model recalibration; therefore the implied upside should be treated cautiously. Key valuation risk drivers are the 10% WACC, terminal growth assumption of 4% and the high share of terminal value (57.1%) in the DCF.
Các luận điểm cần cân nhắc
- High gross margin (51.8%) supports strong incremental cash generation and resilience to pricing pressure.
- Net cash position (model net_debt ≈ VND -66.0 bn) provides flexibility for dividends, buybacks or M&A without leverage stress.
- At current multiples (P/E 12.8, P/B 1.8, EV/EBITDA 9.4), valuation is not stretched relative to historical domestic pharma peers, leaving room for re-rating if growth recovers.
- Revenue and net profit have declined from 2024 to 2025 (revenue from VND 949.7 bn to VND 928.0 bn; net profit from VND 98.7 bn to VND 90.1 bn), signalling near-term growth execution risk.
- Model confidence is low and the instrument is flagged illiquid (avg_volume_2w = 0.0), increasing transaction and mark-to-market risk for large investors.
- Concentrated ownership (largest holder 23.8%, top three hold ~64.9%) reduces free float and heightens minority shareholder governance risk.
Bối cảnh ngành
Vietnamese pharmaceuticals operate under VAS accounting and domestic distribution dynamics; reported margins can differ from international peers due to inventory and pricing practices. The sector’s median implied upside in our coverage universe is c. 12.1%, similar to NDC’s 11.9%, suggesting NDC is roughly in-line with peer re-rating expectations. Key sector themes include OTC/consumer healthcare demand resilience, pricing pressure from generics, and distribution channel consolidation. For banks and large corporates, SBV credit quotas and VAMC bonds matter; for pharma, regulatory approvals, procurement channels and hospital tendering are more relevant. NDC’s listing on UPCoM and very limited foreign room (0.0% reported) further constrain international investor flows compared with HNX/HOSE-listed peers.
Yếu tố rủi ro
- Top-line execution: revenue fell from VND 949.7 bn (2024) to VND 928.0 bn (2025); continued weakness would compress earnings and cash flow.
- Liquidity risk: avg volume two-week = 0.0 and UPCoM listing contribute to illiquidity and wide bid/ask spreads.
- Ownership concentration: top three holders control ~64.9%, limiting free float and raising governance and takeover risk for minority holders.
- Model uncertainty: valuation confidence rated low and model was recalibrated (isotonic), meaning target is sensitive to input assumptions (WACC 10%, terminal g 4%).
- Regulatory & pricing risk: changes in procurement rules, hospital purchasing or reimbursement policies could disproportionately affect domestic pharma margins.
- Dividend/cash distribution: SOE-like payout mandates don't apply, but any change in shareholder distribution policy by controlling owners could alter free float dynamics.
Yếu tố có thể tác động
- A clear return to revenue growth above historical CAGR or recovery to 2024 revenue levels would be a positive re-rating trigger.
- Management announcements on capital allocation (dividend increase, buyback or M&A funded by net cash) could unlock value for minority holders.
- Listing upgrade or improved liquidity (increased market-making, larger free-float block) that reduces the illiquidity discount.
- Positive regulatory outcomes (faster approvals, expanded OTC distribution) that materially expand addressable market.
Đánh giá dấu hiệu kế toán
No Beneish M-Score is provided and forensic red-flag list is empty; there are no explicit forensic flags in the input. Earnings quality is high at 86.1/100, which reduces immediate concern about aggressive accounting. Nonetheless, UPCoM listing and concentrated ownership warrant standard governance diligence by investors.
Lịch sử định giá
The historical model track record spans 12 years with a hit rate of 90.9% and an average modeled upside of 86.4% — a strong historical performance record. Caveat: past hit rate reflects directional calls using >10% upside thresholds and may benefit from selection and survivorship biases; current model confidence is low and the instrument is illiquid, so historical backtest reliability may be reduced for sizing and execution planning.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-11 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.